11 stocks of traditional Chinese medicine rose more than 50% in the year

It is reported that Wang Lian, director of the Information Office of the State Administration of traditional Chinese medicine, recently said that up to now, China has issued 27 national standards of traditional Chinese medicine and more than 470 industrial and organizational standards The construction of the standard system of traditional Chinese medicine has begun to take shape The general principles for the preparation of clinical diagnosis and treatment guidelines of traditional Chinese medicine and the general principles for the preparation of standards for the industry of traditional Chinese medicine have entered the review stage In particular, the draft of the standard system of traditional Chinese medicine has been completed Affected by the news, although the Shanghai stock index fell sharply yesterday, there were still a number of Chinese medicine stocks, such as Guizhou bailing (5.62%), Furui (2.23%), Lingrui Pharmaceutical (1.92%) and so on Since this year, traditional Chinese medicine stocks have performed well Among the 55 tradable traditional Chinese medicine stocks, 53 stocks rose in the year, accounting for 96.36%, of which 11 stocks rose by more than 50%, Xiangxue Pharmaceutical (114.28%), foci Pharmaceutical (86.88%), and zoli Pharmaceutical (82.59%) rose by more than 80% From the basic point of view, the latest data shows that the income of Chinese herbal pieces from January to October increased by 27.9% year-on-year, and the profit increased by 26.5% year-on-year; the income of single month in October increased by 42.0% year-on-year, and the profit increased by 20.4% year-on-year From January to October, the revenue of proprietary Chinese medicine increased by 21.9% and the profit increased by 20.6%; in October, the revenue increased by 10.8% year-on-year and the profit increased by 11.8% year-on-year, and the growth rate of a single month was lower than that of last month In response, market participants pointed out that the rapid growth of Chinese Herbal Pieces in October reflected strong terminal demand The slower growth rate of Chinese patent medicine in October is due to the reduction of some dealers' stock taking into account the subsequent price adjustment expectations of Chinese patent medicine Subsequently, with the increasingly clear policy, the growth rate of Chinese patent medicine consumption is expected to pick up The data further shows that the sales revenue of Chinese patent medicine in China reached 407.9 billion yuan last year, an increase of 21.37% over 2011 In the first three quarters of this year, the sales revenue was 353.6 billion yuan, up 23.44% year on year, slightly higher than the same period last year In recent years, the growth rate of sales revenue of Chinese patent medicine has been higher than that of the whole pharmaceutical manufacturing industry Under the expectation of Chinese patent medicine price reduction, it is expected that the growth rate of revenue of Chinese patent medicine will slow down slightly next year, but it can still maintain the growth rate higher than the overall industry On November 21, the UK medicines and health products authority said that in order to further help people purchase and use safe herbal products, unregistered herbal products will be banned from sale from April 30, 2014 In response to the incident, analysts said that banning unregistered herbal products in the UK was at best an overhaul of the existing market It has little impact on the Chinese medicine sector The export of traditional Chinese medicine mainly faces southeast Asia, Japan and other regions The total import volume of Europe and America is very low, mainly to meet the needs of local Chinese In addition, from the perspective of export categories, most of them are low value-added raw materials or pieces of Chinese herbal medicines, with small profits, so the UK market ban has little impact on the Chinese herbal medicine sector Founder Securities said that the leading enterprises in the modernization of traditional Chinese medicine deserve attention Although the recognition of traditional Chinese medicine in the international market requires the cultural communication of traditional Chinese medicine to take the lead, the European and American market is not a wall of iron With modern research as a means, it can also open the door of the European and American market Strengthening international cooperation and trade of traditional Chinese medicine is one of the key tasks during the 12th Five Year Plan period At the national level, there is a desire to strengthen and expand the industry of traditional Chinese medicine 14 departments, including the Ministry of Commerce and the State Administration of traditional Chinese medicine, put forward several opinions on promoting the development of service trade of traditional Chinese medicine, and support qualified traditional Chinese medicine enterprises Leading enterprises are expected to go abroad The leader of Recommend Tianshili, Zhongxin pharmaceutical, Yiling pharmaceutical, Kangyuan pharmaceutical, Hansen pharmaceutical, Guizhou bailing.